Cornerstone is pleased to welcome Parisa Airia to our team. Parisa is a PhD candidate in Epidemiology at the University of Toronto, having previously completed an MSc in Community Health Sciences from University of Manitoba and an MD from Tehran University. She brings an expertise in data analysis highlighted by her previous graduate work in the areas of disease risk factors, prevention, and treatment at universities of Tehran, Manitoba, and Toronto as well as cancer care centers in Manitoba and Ontario. We have moved to accommodate continued growth. Our new address is: Suite 204, 3228 South Service Road, Burlington, Ontario, L7N 3H8 Increased Adverse Events and Treatment Discontinuation in Patients Switched from Branded Alendronate to Generic Alendronate, presented at 5th Canadian Therapeutics Congress. Quebec City, July 27-August 1, 2008 How many cardiovascular events can be prevented with optimal management of high-risk Canadians?, published in Can J Cardiol. 2008;24(5):363-8. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis, published in Osteoporos Int. 2008;19(5):687-97 Pharmacoeconomic Modeling - Application to Price Setting and Clinical Trial Development, presented at the CBI Effective Product Pricing and Modeling Strategies conference, Philadelphia, April 10-11, 2008 Pricing Considerations in Early Product Development: The Advent of Value-Based Pricing, presented at the CBI Early Stage Commercialization conference, Philadelphia, Feb 25-26, 2008